TC Biopharm (NASDAQ:TCBPW) Trading Down 29.5%
TC Biopharm (NASDAQ:TCBPW) Trading Down 29.5%
TC Biopharm (Holdings) Plc (NASDAQ:TCBPW – Get Rating)'s stock price traded down 29.5% during mid-day trading on Wednesday . The company traded as low as $0.12 and last traded at $0.14. 15,304 shares were traded during trading, a decline of 77% from the average session volume of 67,568 shares. The stock had previously closed at $0.20.
TC 生物製藥 (控股) 有限公司 (NASDAQ: TCBPW — 獲得評級) 的股票價格下跌 29.5% 在星期三中午交易.該公司的交易價格低至 0.12 美元，最後交易價 0.14 美元。在交易期間成交了 15,304 股，較平均交易時段成交量 67,568 股下跌 77%。該股票以前已收盤 0.20 美元。
TC Biopharm Trading Down 29.5 %
TC 生物製藥成交易下跌 29.5%
The business has a fifty day moving average price of $0.13 and a 200-day moving average price of $0.18.
該業務的五十天移動平均價為 0.13 美元，200 天移動平均價格為 0.18 美元。
Institutional Investors Weigh In On TC Biopharm
機構投資者權衡 TC 生物製藥
A hedge fund recently bought a new stake in TC Biopharm stock. Nantahala Capital Management LLC purchased a new stake in TC Biopharm (Holdings) Plc (NASDAQ:TCBPW – Get Rating) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 235,294 shares of the company's stock, valued at approximately $117,000.
對沖基金最近買入了 TC 生物製藥股票的新股份。根據其最近向證券交易委員會提交的文件，南大哈拉資本管理有限責任公司在第一季度購買了 TC 生物製藥（控股）有限公司（NASDAQ：TCBPW-獲得評級）的新股份。該基金購入了該公司股票的 235,294 股，價值約為 11 萬美元。
About TC Biopharm
關於 TC 生物製藥
(Get Rating)
(取得評分)
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its products pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; ImmuniStim, an unmodified cell therapy to treat COVID-19; TCB009 for the GI-tract cancer treatment; and TCB005/TCB006 that are allogeneic co-stimulatory GD-T CAR pre-clinical drug candidates would target antigens expressed on various solid tumor types.
TC 生物醫藥（控股）有限公司是一家臨床階段生物製藥公司，致力於開發基於同種異體伽瑪三角量 T 細胞平台的免疫治療產品。其產品管線包括用於治療急性髓細胞白血病的未改性細胞療法；用於治療 COVID-19 的免疫性細胞療法；用於治療的未改性細胞療法；用於 GI 道癌症治療的 TCB009；以及作為異體共生刺激 GD-T CAR 臨床前藥物候選藥物的 TCB005/TCB006，以及針對各種腫瘤類型表達的抗原的 TCB005/TCB006。
See Also
另請參閱
- Get a free copy of the StockNews.com research report on TC Biopharm (TCBPW)
- Palo Alto Networks Is The Leading Cyber Security Play
- It's Not Time To Buy Toll Brothers, Inc Yet
- Why You Absolutely Must Buy Dividend Stocks This Year
- Furniture Stocks: A Comfortable Way To Ride Out The Storm
- JD.com Getting Desperate or Too Smart for Anyone to Figure Out?
- 索取有關 TC 生物製藥研究報告的免費副本
- 帕洛阿爾托網絡是領先的網絡安全遊戲
- 現在還不是時間購買收費兄弟公司
- 為什麼你絕對必須購買股息股票今年
- 家具股：一個舒適的方式來乘坐風暴
- JD.com 變得絕望或太聰明，任何人都無法弄清楚？
Receive News & Ratings for TC Biopharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TC Biopharm and related companies with MarketBeat.com's FREE daily email newsletter.
接收 TC 生物製藥日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 TC 生物製藥及相關公司的最新新聞和分析師評級的簡要每日摘要。